Genexa is rolling out Acetaminophen Extra Strength and Acetaminophen PM caplets, which it is touting as clean products that contain the same active ingredients and dosages of current category leaders but without artificial dyes, synthetic fillers and other artificial preservatives.
“Now consumers do not have to choose between efficacy and clean ingredients. Our mission of putting people over everything means providing options to those who care about knowing the ingredients in what they are taking,” CEO and co-founder David Johnson said. “We’re bringing options to people’s medicine cabinets they have never had before because we believe that it's time to evolve the decades-old formulas in our everyday medicines without compromising on efficacy.”
The company also shared that Genexa Acetaminophen Extra Strength has 500 mg of the pain reliever acetaminophen, contains the same dosage found in Extra Strength Tylenol, and Genexa Acetaminophen PM has 500mg of the pain reliever acetaminophen and 25 mg of diphenhydramine HCl, has the same dosage found in Tylenol PM.
“In my experience, more and more frequently I am seeing that my patients are doing their best to avoid eating foods that contain artificial additives like dyes, preservatives and assorted other fillers. They have shared with me that they long for medicines that are effective but not full of artificial fillers. I am so happy to finally have a medicine I can recommend to them,” Genexa Medical Advisor Taz Bhatia, a board-certified integrative medicine physician and wellness expert, and founder of CentreSpring MD, said. “This groundbreaking product launch from Genexa is an exciting moment for both the industry and for patients across the country, finally delivering a real choice for people pursuing clean living who are in need of a pain reliver.”
“Genexa’s product launches offer new innovation and a forward-thinking approach that will help serve as a catalyst to the entire consumer pharmaceutical industry,” Brian Perkins, chairman of Genexa said. “Consumers deserve options and transparency in their medicine and Genexa is delivering on this need."
Currently, Walmart is the exclusive mass retailer for Genexa’s acetaminophen products, but the SKUs can also be found at CVS Pharmacy, Amazon.com, and Genexa.com among others.
Dave Wendland, vice president of strategic relations and member of the owner group at HRG, and Corey Paske, business development manager at HRG will be speaking at the virtual ECRM Pet Program, taking place May 2 to 5.
Wendland and Paske will speak during the ‘More Than a Pet Project’ presentation, which is slated to take place on May 4 at 11:00 a.m. ET. During the presentation, the speakers will discuss new market trends and opportunities in the pet industry and share how brands and retailers can best capitalize on pet owners’ dedication to their companions.
“We’re excited to be a part of the Pet Program and offer manufacturers and retailers ideas and inspiration to grow their business,” said Paske. “The American Pet Products Association recently announced the industry reached $123.6 billion in sales in 2021, noting it is the highest level in history. There is a tremendous opportunity in this retail space, and it will be interesting to hear from other participants and learn about new products, services, and process improvements.”
Pet Program participants also can hear HRG president Dawn Vogelsang speak with ECRM’s Joe Tarnowski, vice president of content, about her viewpoint on trends and what’s important in providing a consistent experience for pet shoppers along the omnichannel.
In addition, Colleen Volheim, HRG’s category and research analysis manager, offers merchandising advice in her blog post, “Pet Merchandising 101.”
The Whisps cheese snacks company is entering the pretzel category, expanding its portfolio beyond cheese crisps.
The brand’s Cheese & Pretzel Bites, which contain 100% real, aged parmesan and cheddar cheeses, is made with dairy from four family farms and clean label pretzels, the company said.
“Whisps built its foundation on clean snacks with 100% real, artisanal cheese at its core, and with Whisps Cheese & Pretzel Bites, we’re furthering our commitment to putting actual cheese back in artificial ‘cheez’ snacks,” said John Ghingo, CEO of Whisps. “The pretzel-and-cheese combination isn’t new, but what is new is our obsession with bringing real cheese to the pretzel category.
"These craveworthy, crunchy bites are delicious, nutritious and perfect for any snacking occasion," Ghingo continued. "Bringing our real cheese to pretzels brings protein, reduces carbs and creates a whole new, delicious experience. We cannot wait to see how fans use Whisps Cheese & Pretzel Bites to meet their continuing need for nutritious snacks throughout the day.”
Available in cheddar, honey mustard and everything flavors, Whisps Cheese & Pretzel Bites contain 7 g of protein and 0 g of sugar per serving, the company said.
Retailing for $4.49, Whisps Cheese & Pretzel Bites can be found at Kroger and Amazon.com.
The American Pharmacists Association announced that its 2022–2023 class of executive residents has been selected.
The APhA Executive Residency Program, which was designed to provide pharmacists with training and experience in the fundamentals of association management, supports APhA’s vision, mission and brand identity as the leading professional organization representing pharmacists in all practice settings.
Residents contribute to APhA’s strategic priorities and operations through collaborations with staff teams across the organization.
The members of the 2022–2023 class of executive residents are:
Aneesh Asokan, from Southern Illinois University Edwardsville School of Pharmacy in Edwardsville, Ill. Asokan will serve on the Board of Pharmacy Specialties during their residency.
Isabella Blankenship, from Drake University College of Pharmacy and Health Sciences in Des Moines, Iowa. She will serve in APhA’s practice and government affairs departments during their residency.
Mariecus Jarvis, from Howard University College of Pharmacy in Washington, D.C. Jarvis will serve in APhA’s education department during their residency.
Shivani Modi, from Notre Dame of Maryland University School of Pharmacy in Baltimore, MD. Modi will serve in APhA’s practice and government affairs departments during their residency.
Lauren Walters, from the University of South Carolina College of Pharmacy in Columbia, SC. She will serve in APhA’s publishing department during their residency.
Brooke Whittington, from the University of Arizona College of Pharmacy in Tucson, AZ. She will serve in APhA’s education department during their residency.
The application period for the next class of executive residents will open in the Fall of 2022.
Heinz innovates burger eating experience with Dip & Crunch
Heinz is changing the way consumers enjoy their meals — specifically burgers.
New from the brand is Dip & Crunch, which combines a sauce with crisp potato crunchers inside a two-in-one package designed to elevate the burger-eating experience, the company said.
Featuring a burger sauce made from tomato puree, molasses, sun-dried tomatoes, garlic powder, tamarind concentrate, onion powder and spices, the crisp crunchers also included in the package were designed to cling to the smooth sauce when dunked.
“Here at Heinz, we recognize the magic in making memories on burger night thanks to the way our condiments uniquely elevate the classic burger,” said Ashleigh Gibson, brand director at Heinz. “As we continue to reimagine mealtime, we’re excited to offer a solution for consumers looking for accessible dipping sauces and unique textures to help further embrace the fun of cooking and eating at home.”
Heinz’s Dip & Crunch is available in regular and spicy varieties and can be found nationwide at such retailers as Walmart, Meijer, Target and Giant.
Alembic’s subsidiary, Aleor has received the Food and Drug Administration’s green light for clobetasol propionate foam, 0.05%.
The product is the generic of Mylan’s Olux Foam.
It is a corticosteroid indicated for the treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients aged 12 years old and older.
Clobetasol propionate foam has a market value of roughly $10 million for the 12 months ending December 2021, according to IQVIA.